Kura Oncology, Inc. . Full-time Employee Directory
Biotechnology ResearchCalifornia, United States201-500 Employees
Kura Oncology, Inc. is a mid-sized biotechnology company based in San Diego, California, focused on cancer therapeutics. It operates in the field of precision oncology, aiming to understand mechanisms of treatment resistance to guide the development of combination regimens that attack tumors from multiple directions. The company has commercialized KOMZIFTI (ziftomenib), an oral menin inhibitor approved by the FDA for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. In addition to menin inhibition, Kura conducts work in farnesyl transferase inhibition as part of its research portfolio. In 2026 the company initiated a Phase II trial of ziftomenib for AML in collaboration with Kyowa Kirin.